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Since my talk is called Research in Jeopardy, I will introduce 
the subject with 5 questions in a Jeopardy game format, then 
take each one and use them to discuss the true objective of my 
talk, Research in Jeopardy.
1. Daniel Bovet won the 1957 Nobel Prize for Physiology 
or Medicine for his discovery of this substance that 
served as the basis for an effective therapy against 
allergic reactions and acid-related diseases. What is 
this substance? 
The first answer is Histamine.
Let’s start by looking at a typical parenteral nutrition (PN) 
bag. As most of you know the story of PN’s development, I 
will tell a different story, one that relates to a single additive 
found in almost every bag of PN, ranitidine, a histamine-2 
antagonist.
In fact, this story is really an investigation that moves from 
obscurity to discovery and then on to commercial success. The 
story began in 1910 with the discovery by Henry Dale of hista-
mine on a group of unusual mold formations found on the grain 
rye. Dale worked for Wellcome Laboratories, a pharmaceutical 
company, and for this discovery he was subsequently knighted 
and awarded the Nobel Prize.1 In this case, an initial invest-
ment in research by the pharmaceutical industry led to an 
entirely new venue of investigation. This was followed in 1937 
by the discovery by a number of university investigators of the 
first antihistamine, one that would eventually become a com-
mon antihistamine that is, of course, now used by millions for 
cold and allergy symptoms.
In the 1950s, several investigators identified the unusual 
finding of histamine within the wall of the stomach, but its 
function and significance remained unknown. However, based 
on this scant preliminary evidence, the pharmaceutical indus-
try again took up the investigation of antihistamines, this time 
under James Black and his research group. Their radical strat-
egy was to block H2 action and control stomach acid secretion. 
Some 16 years later, they identified the first H2 antagonist, a 
compound that we now call Tagamet® or cimetidine, a drug 
that has a profound benefit in the treatment and prevention of 
peptic ulcers and is available at any pharmacy counter.
So 100 years later, one line of drugs, 62 years of investment 
and research, and the dedication and commitment of government 
funding, pharmaceutical support, and academic insight were able 
to achieve an incredible line of therapeutics. The total commer-
cial sales for this class of drug totals roughly $58 billion from 
1979 to today.1
2. What number do you get when you add 36 plus 36 and 
subtract 14?
The second Jeopardy answer is the number 58, or $58 billion, 
almost twice the 2014 National Institutes of Health (NIH) 
yearly budget.2
When you look at this incredible achievement, you observe 
that success was entirely due to a partnership between 3 critical 
entities: government funding, academic investigation, and the 
pharmaceutical industry. In synchrony with each other, this part-
nership has produced some incredible achievements, including 
novel drugs and important nutrient products, all of which have 
had an enormous impact on our patients’ health (Figure 1).
However, when one of these elements fails, the gears falls 
out of synchrony. The results have far graver consequences 
than what may initially be perceived.
Where are we today? In fact, I am among the vast majority of 
researchers who are convinced that we have fallen out of this 
synchronized state.2 Unfortunately, most pharmaceutical corpo-
rations and government funding agencies no longer demonstrate 
the dedication or commitment to support such long-term endeav-
ors as the development of H2 antagonists. Many corporations 
are driven by yearly or even quarterly profit reports. A decline 
during any quarter may mean moving away from critical areas 
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of novel investigation, some of which might mean the next great 
nutrition advancement. A 62-year commitment just does not fly 
in our current world. Furthermore, most NIH study sections 
rarely support projects that last beyond 1–2 funding cycles.
3. What year did the song, “We Built This City,” by 
Jefferson Starship reach number 1 as a billboard chart 
single?
Our next Jeopardy answer is 1985.
While there had been tremendous increases in NIH funding 
in the early 1980s, then another jump in funding around the 
year 2000, when corrected for inflation, funding for U.S. 
research has not increased since 1985.3
In fact, funding has actually declined over the past decade. 
NIH funding, the key driver of innovative research and knowl-
edge in U.S. academic institutions, has not changed in over 15 
years and has declined by 20% since 2004.
So how does this match up with the general economic reali-
ties in the United States? During virtually this same period of 
time, despite low inflation rates, prices have not remained fro-
zen. Looking at the economy 30 years ago in 1984 dollars, 
median salaries, the cost of a new home, and the price of a car 
have gone up dramatically.
4.  Which animated Disney movie has main characters 
named Anna and Elsa?
The next Jeopardy answer is Frozen.
I submit that research scientists have entered into a true ice 
age. In fact, the term Frozen very accurately describes our cur-
rent state of research in the United States.
Classic funding via an NIH R01 grant, the main mechanism 
for most academic researchers, has remained fixed at $250,000 
for the past 25 years. This leaves researchers in the terrible 
predicament of paying 2014 wages and 2014 laboratory supply 
costs with funding levels from almost 3 decades ago. 
Investigators are forced to go to extreme measures with a 
resulting decline in research productivity, fewer successfully 
funded laboratories, and far fewer young investigators who 
want to take up this challenge.
What are the implications of this decline? In a country with 
an economy that is otherwise growing, fixed levels of funding 
mean that far fewer scientists will receive NIH funding. The 
chances of a researcher receiving funding on a grant proposal 
after the first submission is only 8.5%, and even after resub-
mission, this rises only to 17%. One would do better with gam-
bling at a blackjack table than submitting an NIH grant. And 
for those who do not make the narrow funding cut, the outcome 
is becoming quite dismal.
In fact, in 2014, more than 3500 established NIH investiga-
tors shut down their laboratories permanently, and 47% of sci-
entists abandoned an area of potentially fruitful investigation. 
Think about that ergot mold growing on rye that generated $58 
billion—would that ever have a chance of getting funded in 
this environment?
The loss of each laboratory leads to the loss of knowledge, 
experience, and a line of work that may never be replaced. The 
closure of a laboratory also represents the loss of future ideas 
and innovations. As each laboratory closes, one also closes an 
opportunity for our young scientists. Young and bright scien-
tists begin in research as postdoctoral fellows, yet many move 
from research into other careers, such as consultancy, industry 
sales, clinical work, or teaching. While the reasons are varied, 
each clearly sees that the prospects of an academic research 
career are not what they once were. Less than 16% of PhDs 
will ever get a faculty position, and fewer than 10% of PhDs 
ever become a principal investigator.
5.  Which Greek mythology character ignored his father’s 
warnings and flew too close to the Sun, melting the 
wings that his father had made for them both to escape 
the island on which they were imprisoned by King 
Minos of Crete?
So now for our “final” Jeopardy question—the tough one: 
Icarus.
In an outstanding recent book by Seth Godin, The Icarus 
Deception, the author relates the ancient mythological story of 
Daedalus and his son Icarus, who are prisoners on the island of 
Crete. They cleverly escaped from their captor, King Minos, by 
building wings of wax and feathers. Now, many of us will 
remember the part about the father warning Icarus about flying 
too high and letting his wings melt. In fact, Daedalus warns 
Icarus of an even greater danger: flying too low, getting his 
wings wet on the seawater, and losing his lift.
To quote Godin: “It’s far more dangerous to fly too low than 
too high, because it feels safe to fly low. We settle for low 
expectations and small dreams and guarantee ourselves less 
than we are capable of.”4
I chose this example, as I know our research efforts in the 
United States are flying dangerously too low. We are setting 
Figure 1. Partnerships to achieve research advancements.
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our expectations far too low. And, just as Daedalus warned his 
son, we are of course setting ourselves up for a potentially ter-
rible demise.
So, what options do we as medical professionals have?
We are at a cusp, for without significant and doubling of 
NIH funding over the next decade, we will see that empty 
research laboratories and online advertisements selling off 
laboratory equipment will be our only legacy.
However, we can take a different direction, and I firmly 
believe we can move ahead. The past 20 years have resulted in 
the most dramatic advancements in all of medical history: the 
cloning of the human genome, stem cell technology, antiviral 
therapies, advanced imaging, and technological marvels such 
as robotic surgery.
Yet this is really just the beginning. We are at the verge of 
some incredible achievements in human health, all of which 
directly affect how we as medical professionals will nutrition-
ally care for our patients.
Many of us may have heard President Obama talk about 
personalized medicine being the next forefront. In many ways, 
nutrition is a prime example of how we can tailor the nutrition 
needs of our patients in a highly individualized fashion that 
addresses their unique genetic and metabolic processes. 
Furthermore, advanced bioinformatics will allow us to align 
not just the human genome but also proteomics, metabolomics, 
and metagenomics. Tissue engineering and nanotechnology 
innovations hold tremendous promise for treating diseased 
organs and cancers in ways we have never before conceived. 
We should not let these incredibly valuable opportunities pass 
us by!
But what can we do?
First, I would like to call your attention to what the American 
Society for Parenteral and Enteral Nutrition (ASPEN) is doing 
to support research. Over the past 3 years, ASPEN, through the 
great work of Peggi Guenter and our Research Committee, has 
developed a detailed research agenda.5 This agenda serves to 
help guide current and future researchers and investigators to 
the most critical areas where new research in nutrition support 
is needed. This was published 1 year ago in the Journal of 
Parenteral and Enteral Nutrition, and I ask that you take a look 
at this outstanding work.
Second, I want to emphasize the incredible work that the 
ASPEN Rhoads Research Foundation is doing. The 2015 
Rhoads grant awardees are a spectacular group of individuals. 
Each year as I look at the quality of research in these proposals, 
I am completely blown away by how far our nutrition research 
efforts have advanced. Since 1994, more than $1.3 million has 
been awarded to over 65 individuals. Many of these awards 
have been to men and women in the audience today who repre-
sent our current and future nutrition leaders. I ask that each of 
you strongly consider making a contribution to this foundation 
and help to secure our future legacy in nutrition research.
Third, as Congress decides the next budget priorities this 
winter, it is very important that your senators and congressional 
representatives hear from you. While the Congress is set to keep 
research funding at Frozen levels, the Federation of American 
Societies for Experimental Biology and several other scientific 
groups have advocated for significant increases this year. I want 
to emphasize that this is not a question of Republicans vs 
Democrats. We need to speak as a common group for what is 
needed for our patients. With the U.S. economy stronger than it 
has been in the past decade, we should not let this opportunity 
pass us by.
Fourth, I encourage the leaders of our nutrition and pharma-
ceutical corporations to invest in research and development 
efforts to improve the nutrition care of our patients. They play 
a critical role in our success.
Each attendee to Clinical Nutrition Week and member of 
ASPEN will receive a brief message from me today. The mes-
sage will guide you to contribute to our Rhoads research foun-
dation. It will also provide you with a link to communicate to 
your congressional representatives and let them know that you 
want to see research funding advance in our country. I ask each 
of you to make a contribution and act as an advocate for 
research. If each of you in this audience could contribute $5, 
we could eventually help to fund 2 more small research grants. 
Please do not let this message slip by. If we do not act now, the 
future we are creating for our next generation of researchers 
will not be a pretty one!
To close, I hope that your time at Clinical Nutrition Week 
is enlightening, educational, and most of all enjoyable. I look 
forward to interacting with many of you over the next few 
days.
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